Contrasting Selecta Biosciences (SELB) & Its Peers

Selecta Biosciences (NASDAQ: SELB) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Selecta Biosciences to related businesses based on the strength of its earnings, risk, dividends, institutional ownership, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Selecta Biosciences and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Selecta Biosciences 0 0 2 0 3.00
Selecta Biosciences Competitors 1261 3658 12195 260 2.66

Selecta Biosciences presently has a consensus target price of $29.00, suggesting a potential upside of 233.72%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.37%. Given Selecta Biosciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Selecta Biosciences is more favorable than its peers.

Valuation & Earnings

This table compares Selecta Biosciences and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Selecta Biosciences $8.08 million -$36.21 million -2.80
Selecta Biosciences Competitors $271.74 million -$19.68 million 75.89

Selecta Biosciences’ peers have higher revenue and earnings than Selecta Biosciences. Selecta Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

55.0% of Selecta Biosciences shares are owned by institutional investors. Comparatively, 49.5% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 41.9% of Selecta Biosciences shares are owned by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


This table compares Selecta Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Selecta Biosciences -1,918.59% -100.06% -61.41%
Selecta Biosciences Competitors -5,252.48% -110.04% -37.41%

Risk and Volatility

Selecta Biosciences has a beta of -5.56, suggesting that its share price is 656% less volatile than the S&P 500. Comparatively, Selecta Biosciences’ peers have a beta of 1.82, suggesting that their average share price is 82% more volatile than the S&P 500.


Selecta Biosciences beats its peers on 7 of the 12 factors compared.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply